PMC

Kaplan-Meier Curves of ADRB1 Arg/Gly 389 effect on heart failure survival A. β-blocker untreated subjects stratified by ADRB1 389Gly carrier status (top inset, Caucasian Americans; bottom inset, African Americans). B. β-blocker treated subjects stratified by ADRB1 389Gly carrier status (top inset, Caucasian Americans; bottom inset, African Americans). Solid line, Arg/Arg 389; dashed line, Gly 389 carriers.

Kaplan-Meier Curves of GRK5 Gln/Leu 41 effect on heart failure survival. A. β-blocker untreated subjects stratified by GRK5 41Leu carrier status (top inset, Caucasian Americans; bottom inset, African Americans). B. β-blocker treated subjects stratified by GRK5 41Leu carrier status (top inset, Caucasian Americans; bottom inset, African Americans). Solid line, Gln/Gln 41; dashed line, Leu 41 carriers.

Kaplan-Meier Curves of β-blocker treatment effect on heart failure survival A. Combined heart failure cohort, stratified by β-blocker usage (top inset, Caucasian Americans; bottom inset, African Americans). Solid line, β-blocker untreated; dashed line, β-blocker treated. B. Survival of β-blocker untreated heart failure subjects, stratified by race. C. Survival of β-blocker treated heart failure subjects, stratified by race. Solid line, Caucasian; dashed line, African American.

Kaplan-Meier Curves of β-blocker treatment effect on heart failure survival in subjects matched for ADRB1 Gly 389 and GRK5 Gln 41 homozygous genotype. A. Combined heart failure cohort, stratified by β-blocker usage (top inset, Caucasian Americans; bottom inset, African Americans). Solid line, β-blocker untreated; dashed line, β-blocker treated. B. Survival of β-blocker untreated heart failure subjects, stratified by race. C. Survival of β-blocker treated heart failure subjects, stratified by race. Solid line, Caucasian; dashed line, African American.